Solvency ratios also known as long-term debt ratios measure a company ability to meet long-term obligations.
Paying user area
Try for free
Regeneron Pharmaceuticals Inc. pages available for free this week:
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Analysis of Geographic Areas
- Enterprise Value (EV)
- Capital Asset Pricing Model (CAPM)
- Net Profit Margin since 2005
- Operating Profit Margin since 2005
- Return on Equity (ROE) since 2005
- Price to Earnings (P/E) since 2005
- Price to Book Value (P/BV) since 2005
- Aggregate Accruals
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Regeneron Pharmaceuticals Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Solvency Ratios (Summary)
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
- Debt Ratios
- The company exhibits a consistent downward trend in its debt levels relative to equity, capital, and assets over the five-year period. The debt to equity ratio decreases from 0.24 in 2020 to 0.09 in 2024, indicating a reduction in reliance on debt financing compared to shareholder equity. This trend persists even when operating lease liabilities are included, reflecting a similar decline from 0.25 to 0.1.
- Similarly, the debt to capital ratio falls from 0.2 to 0.08, and debt to assets ratio decreases from 0.16 to 0.07 during the same period. Inclusion of operating lease liabilities slightly adjusts these figures, but the overall trend remains a steady reduction in debt burden relative to the company's capital structure and asset base.
- Financial Leverage
- Financial leverage demonstrates a moderate decline from 1.56 in 2020 to a low point of 1.27 in 2023, followed by a slight increase to 1.29 in 2024. This suggests an overall decrease in the use of debt relative to equity, with a minor uptick in the latest year that may reflect changes in capital management or external financing strategies.
- Interest and Fixed Charge Coverage
- Interest coverage ratios reflect generally strong and fluctuating earnings capacity relative to interest expenses. The ratio peaks markedly at 163.75 in 2021, indicating exceptional ability to cover interest payments, then declines to 58.52 in 2023 before improving again to 87.59 in 2024. Despite these fluctuations, the ratios remain well above 1, signifying adequate interest payment coverage throughout the period.
- Fixed charge coverage follows a similar pattern, rising sharply in 2021 to 138.96, then dropping to 46.55 in 2023, with a modest recovery to 53.13 in 2024. These values also suggest that the company maintains sufficient coverage of fixed financial obligations despite variability over time.
- Summary Insights
- Overall, the financial data indicate a deliberate reduction in debt levels relative to equity, capital, and assets, reflecting a more conservative capital structure over the years analyzed. The company’s ability to service its debt remains strong, as evidenced by robust interest and fixed charge coverage ratios. Fluctuations in these coverage metrics warrant further examination but do not currently signify financial distress. The slight increase in financial leverage in the most recent year could imply renewed borrowing or changes in equity levels, meriting ongoing monitoring.
Debt Ratios
Coverage Ratios
Debt to Equity
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||
Finance lease liabilities, current portion | ||||||
Long-term debt | ||||||
Finance lease liabilities, excluding current portion | ||||||
Total debt | ||||||
Stockholders’ equity | ||||||
Solvency Ratio | ||||||
Debt to equity1 | ||||||
Benchmarks | ||||||
Debt to Equity, Competitors2 | ||||||
AbbVie Inc. | ||||||
Amgen Inc. | ||||||
Bristol-Myers Squibb Co. | ||||||
Danaher Corp. | ||||||
Eli Lilly & Co. | ||||||
Gilead Sciences Inc. | ||||||
Johnson & Johnson | ||||||
Merck & Co. Inc. | ||||||
Pfizer Inc. | ||||||
Thermo Fisher Scientific Inc. | ||||||
Vertex Pharmaceuticals Inc. | ||||||
Debt to Equity, Sector | ||||||
Pharmaceuticals, Biotechnology & Life Sciences | ||||||
Debt to Equity, Industry | ||||||
Health Care |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 2024 Calculation
Debt to equity = Total debt ÷ Stockholders’ equity
= ÷ =
2 Click competitor name to see calculations.
The financial data reveals several notable trends over the five-year period under review.
- Total Debt
- The total debt remained relatively stable, with only a slight increase from 2,695,700 thousand US dollars in 2020 to 2,704,400 thousand US dollars in 2024. This marginal change suggests a conservative approach to debt management, maintaining debt levels that do not significantly fluctuate over time.
- Stockholders’ Equity
- Stockholders’ equity showed a strong and consistent upward trajectory, increasing from 11,025,300 thousand US dollars in 2020 to 29,353,600 thousand US dollars in 2024. This substantial growth indicates a significant accumulation of retained earnings or capital injections, reflecting improved company valuation and increased financial strength.
- Debt to Equity Ratio
- The debt to equity ratio declined steadily from 0.24 in 2020 to 0.09 in 2024. This downward trend further confirms the strengthening of the company's equity base relative to its debt obligations, suggesting a lower financial risk profile and enhanced solvency over the period analyzed.
Overall, the data indicates a solid improvement in the company’s financial position, highlighted by a robust increase in equity and controlled debt levels. The declining debt to equity ratio reflects enhanced financial stability and potential for greater investment capacity.
Debt to Equity (including Operating Lease Liability)
Regeneron Pharmaceuticals Inc., debt to equity (including operating lease liability) calculation, comparison to benchmarks
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||
Finance lease liabilities, current portion | ||||||
Long-term debt | ||||||
Finance lease liabilities, excluding current portion | ||||||
Total debt | ||||||
Operating lease liabilities, current (included in Accrued expenses and other current liabilities) | ||||||
Operating lease liabilities, noncurrent (included in Other noncurrent liabilities) | ||||||
Total debt (including operating lease liability) | ||||||
Stockholders’ equity | ||||||
Solvency Ratio | ||||||
Debt to equity (including operating lease liability)1 | ||||||
Benchmarks | ||||||
Debt to Equity (including Operating Lease Liability), Competitors2 | ||||||
AbbVie Inc. | ||||||
Amgen Inc. | ||||||
Bristol-Myers Squibb Co. | ||||||
Danaher Corp. | ||||||
Eli Lilly & Co. | ||||||
Gilead Sciences Inc. | ||||||
Johnson & Johnson | ||||||
Merck & Co. Inc. | ||||||
Pfizer Inc. | ||||||
Thermo Fisher Scientific Inc. | ||||||
Vertex Pharmaceuticals Inc. | ||||||
Debt to Equity (including Operating Lease Liability), Sector | ||||||
Pharmaceuticals, Biotechnology & Life Sciences | ||||||
Debt to Equity (including Operating Lease Liability), Industry | ||||||
Health Care |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 2024 Calculation
Debt to equity (including operating lease liability) = Total debt (including operating lease liability) ÷ Stockholders’ equity
= ÷ =
2 Click competitor name to see calculations.
The analysis of the financial data over the five-year period reveals certain notable trends related to the company's capital structure and leverage.
- Total Debt (including operating lease liability)
- The total debt remains relatively stable from 2020 to 2023, with minor fluctuations around the 2,760,000 US$ in thousands mark. However, in 2024, there is a slight increase to approximately 2,938,800 US$ in thousands, indicating a modest rise in the company's obligations. This suggests a cautious approach to borrowing, with a relatively constant debt load over the initial four years followed by a moderate increase in the latest year.
- Stockholders’ Equity
- Stockholders’ equity exhibits a strong upward trend throughout the period. Starting at approximately 11,025,300 US$ in thousands in 2020, it grows substantially each year, reaching nearly 29,353,600 US$ in thousands by 2024. This significant increase reflects consistent growth in retained earnings or additional equity financing, strengthening the company's financial position and capacity to absorb debt.
- Debt to Equity Ratio (including operating lease liability)
- The debt to equity ratio shows a declining trend, decreasing from 0.25 in 2020 to 0.10 in 2024. This decline implies that the company's leverage is reducing over time, with equity growing at a faster rate than debt. A lower ratio typically suggests improved financial stability and reduced risk from debt obligations.
Overall, the data indicates a strategic shift toward strengthening the equity base and reducing reliance on debt. The stable total debt combined with robust equity growth results in a lower debt to equity ratio, which may enhance the company’s creditworthiness and financial flexibility. Despite a slight increase in debt in the last year, the leverage remains low relative to equity, consistent with conservative financial management practices observed during the period.
Debt to Capital
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||
Finance lease liabilities, current portion | ||||||
Long-term debt | ||||||
Finance lease liabilities, excluding current portion | ||||||
Total debt | ||||||
Stockholders’ equity | ||||||
Total capital | ||||||
Solvency Ratio | ||||||
Debt to capital1 | ||||||
Benchmarks | ||||||
Debt to Capital, Competitors2 | ||||||
AbbVie Inc. | ||||||
Amgen Inc. | ||||||
Bristol-Myers Squibb Co. | ||||||
Danaher Corp. | ||||||
Eli Lilly & Co. | ||||||
Gilead Sciences Inc. | ||||||
Johnson & Johnson | ||||||
Merck & Co. Inc. | ||||||
Pfizer Inc. | ||||||
Thermo Fisher Scientific Inc. | ||||||
Vertex Pharmaceuticals Inc. | ||||||
Debt to Capital, Sector | ||||||
Pharmaceuticals, Biotechnology & Life Sciences | ||||||
Debt to Capital, Industry | ||||||
Health Care |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 2024 Calculation
Debt to capital = Total debt ÷ Total capital
= ÷ =
2 Click competitor name to see calculations.
The financial data indicates a consistent pattern in the capital structure and debt levels over the analyzed period.
- Total Debt
- The total debt has shown a very slight increase from 2,695,700 thousand US dollars at the end of 2020 to 2,704,400 thousand US dollars by the close of 2024. This suggests that the company has maintained a relatively stable debt level, with marginal increments over the five-year period.
- Total Capital
- Total capital has experienced a significant and steady increase over the years, rising from 13,721,000 thousand US dollars at the end of 2020 to 32,058,000 thousand US dollars at the end of 2024. This indicates substantial growth in the company's capital base, more than doubling within the timeframe.
- Debt to Capital Ratio
- The debt to capital ratio has decreased consistently from 0.20 in 2020 to 0.08 in 2024. This downward trend highlights a declining reliance on debt financing relative to the overall capital. The company has effectively reduced its financial leverage as total capital increased while total debt remained relatively constant.
Overall, the data reflects a strategic strengthening of the capital structure, with the company expanding its capital resources significantly while maintaining debt levels nearly flat. This improvement in the debt to capital ratio over the years demonstrates enhanced financial stability and potentially lower financial risk.
Debt to Capital (including Operating Lease Liability)
Regeneron Pharmaceuticals Inc., debt to capital (including operating lease liability) calculation, comparison to benchmarks
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||
Finance lease liabilities, current portion | ||||||
Long-term debt | ||||||
Finance lease liabilities, excluding current portion | ||||||
Total debt | ||||||
Operating lease liabilities, current (included in Accrued expenses and other current liabilities) | ||||||
Operating lease liabilities, noncurrent (included in Other noncurrent liabilities) | ||||||
Total debt (including operating lease liability) | ||||||
Stockholders’ equity | ||||||
Total capital (including operating lease liability) | ||||||
Solvency Ratio | ||||||
Debt to capital (including operating lease liability)1 | ||||||
Benchmarks | ||||||
Debt to Capital (including Operating Lease Liability), Competitors2 | ||||||
AbbVie Inc. | ||||||
Amgen Inc. | ||||||
Bristol-Myers Squibb Co. | ||||||
Danaher Corp. | ||||||
Eli Lilly & Co. | ||||||
Gilead Sciences Inc. | ||||||
Johnson & Johnson | ||||||
Merck & Co. Inc. | ||||||
Pfizer Inc. | ||||||
Thermo Fisher Scientific Inc. | ||||||
Vertex Pharmaceuticals Inc. | ||||||
Debt to Capital (including Operating Lease Liability), Sector | ||||||
Pharmaceuticals, Biotechnology & Life Sciences | ||||||
Debt to Capital (including Operating Lease Liability), Industry | ||||||
Health Care |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 2024 Calculation
Debt to capital (including operating lease liability) = Total debt (including operating lease liability) ÷ Total capital (including operating lease liability)
= ÷ =
2 Click competitor name to see calculations.
The analysis of the financial data reveals several notable trends concerning the company's capital structure over the reported periods.
- Total debt (including operating lease liability)
- The total debt has shown a gradual increase from US$2,763,900 thousand at the end of 2020 to US$2,938,800 thousand by the end of 2024. The growth is relatively modest, suggesting a stable debt level with slight increments over the five-year period.
- Total capital (including operating lease liability)
- The total capital has experienced significant growth, rising from US$13,789,200 thousand in 2020 to US$32,292,400 thousand in 2024. This steady and substantial increase indicates that the company has expanded its overall capital base considerably, potentially through equity funding, retained earnings, or other capital inflows.
- Debt to capital ratio (including operating lease liability)
- The debt to capital ratio has steadily declined from 0.20 in 2020 to 0.09 in 2024. This decreasing trend suggests an improvement in the company’s leverage profile, with less reliance on debt financing relative to its total capital. The reduction in leverage could imply a more conservative financial strategy or enhanced capacity to raise capital through non-debt sources.
In summary, while total debt has increased slightly, total capital has grown at a much faster rate, resulting in a markedly lower debt to capital ratio. This trend reflects a strengthening capital structure with reduced financial risk and greater equity participation over the observed periods.
Debt to Assets
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||
Finance lease liabilities, current portion | ||||||
Long-term debt | ||||||
Finance lease liabilities, excluding current portion | ||||||
Total debt | ||||||
Total assets | ||||||
Solvency Ratio | ||||||
Debt to assets1 | ||||||
Benchmarks | ||||||
Debt to Assets, Competitors2 | ||||||
AbbVie Inc. | ||||||
Amgen Inc. | ||||||
Bristol-Myers Squibb Co. | ||||||
Danaher Corp. | ||||||
Eli Lilly & Co. | ||||||
Gilead Sciences Inc. | ||||||
Johnson & Johnson | ||||||
Merck & Co. Inc. | ||||||
Pfizer Inc. | ||||||
Thermo Fisher Scientific Inc. | ||||||
Vertex Pharmaceuticals Inc. | ||||||
Debt to Assets, Sector | ||||||
Pharmaceuticals, Biotechnology & Life Sciences | ||||||
Debt to Assets, Industry | ||||||
Health Care |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 2024 Calculation
Debt to assets = Total debt ÷ Total assets
= ÷ =
2 Click competitor name to see calculations.
- Total Debt
- The total debt remained relatively stable over the five-year period, showing a slight incremental increase from 2,695,700 thousand US dollars in 2020 to 2,704,400 thousand US dollars in 2024. This marginal change indicates that the company maintained consistent debt levels with minimal additional borrowing over the years.
- Total Assets
- Total assets exhibited a strong upward trend, increasing substantially from 17,163,300 thousand US dollars in 2020 to 37,759,400 thousand US dollars in 2024. This represents more than a twofold increase in total assets across the five years, suggesting significant growth or expansion activities resulting in a larger asset base.
- Debt to Assets Ratio
- The debt to assets ratio declined steadily from 0.16 in 2020 to 0.07 in 2024. This downward trend reflects an improvement in the company’s financial leverage position, as assets grew markedly while total debt remained relatively flat. The diminishing ratio suggests enhanced asset coverage of liabilities and potentially lower financial risk over time.
Debt to Assets (including Operating Lease Liability)
Regeneron Pharmaceuticals Inc., debt to assets (including operating lease liability) calculation, comparison to benchmarks
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||
Finance lease liabilities, current portion | ||||||
Long-term debt | ||||||
Finance lease liabilities, excluding current portion | ||||||
Total debt | ||||||
Operating lease liabilities, current (included in Accrued expenses and other current liabilities) | ||||||
Operating lease liabilities, noncurrent (included in Other noncurrent liabilities) | ||||||
Total debt (including operating lease liability) | ||||||
Total assets | ||||||
Solvency Ratio | ||||||
Debt to assets (including operating lease liability)1 | ||||||
Benchmarks | ||||||
Debt to Assets (including Operating Lease Liability), Competitors2 | ||||||
AbbVie Inc. | ||||||
Amgen Inc. | ||||||
Bristol-Myers Squibb Co. | ||||||
Danaher Corp. | ||||||
Eli Lilly & Co. | ||||||
Gilead Sciences Inc. | ||||||
Johnson & Johnson | ||||||
Merck & Co. Inc. | ||||||
Pfizer Inc. | ||||||
Thermo Fisher Scientific Inc. | ||||||
Vertex Pharmaceuticals Inc. | ||||||
Debt to Assets (including Operating Lease Liability), Sector | ||||||
Pharmaceuticals, Biotechnology & Life Sciences | ||||||
Debt to Assets (including Operating Lease Liability), Industry | ||||||
Health Care |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 2024 Calculation
Debt to assets (including operating lease liability) = Total debt (including operating lease liability) ÷ Total assets
= ÷ =
2 Click competitor name to see calculations.
The financial data reveals several notable trends regarding debt and assets over the five-year period ending December 31, 2024.
- Total Debt (Including Operating Lease Liability)
- The total debt has shown a slight upward trajectory from approximately $2.76 billion in 2020 to about $2.94 billion in 2024. While the increase is modest, the debt figures have remained relatively stable, fluctuating minimally year over year.
- Total Assets
- There has been a significant increase in total assets during the period. Starting at roughly $17.16 billion in 2020, total assets nearly doubled by 2024 to approximately $37.76 billion. This upward trend suggests considerable growth and investment in the company's asset base over these years.
- Debt to Assets Ratio (Including Operating Lease Liability)
- The debt to assets ratio has decreased steadily from 0.16 in 2020 to 0.08 in 2024. This decline indicates that while total debt has remained fairly constant, it constitutes a smaller proportion of the growing asset base. The reduction in leverage ratio suggests an improvement in the company's financial stability and a stronger equity position relative to debt.
Overall, the data exhibits robust asset growth with controlled and stable debt levels, leading to a declining leverage ratio. This pattern reflects a strengthening balance sheet with increased capacity to support operations and potential expansion without proportionally increasing financial risk.
Financial Leverage
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||
Total assets | ||||||
Stockholders’ equity | ||||||
Solvency Ratio | ||||||
Financial leverage1 | ||||||
Benchmarks | ||||||
Financial Leverage, Competitors2 | ||||||
AbbVie Inc. | ||||||
Amgen Inc. | ||||||
Bristol-Myers Squibb Co. | ||||||
Danaher Corp. | ||||||
Eli Lilly & Co. | ||||||
Gilead Sciences Inc. | ||||||
Johnson & Johnson | ||||||
Merck & Co. Inc. | ||||||
Pfizer Inc. | ||||||
Thermo Fisher Scientific Inc. | ||||||
Vertex Pharmaceuticals Inc. | ||||||
Financial Leverage, Sector | ||||||
Pharmaceuticals, Biotechnology & Life Sciences | ||||||
Financial Leverage, Industry | ||||||
Health Care |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 2024 Calculation
Financial leverage = Total assets ÷ Stockholders’ equity
= ÷ =
2 Click competitor name to see calculations.
The analysis of the financial data reveals several notable trends over the five-year period from 2020 to 2024.
- Total assets
- The total assets exhibit a consistent upward trajectory, increasing steadily each year. Starting at approximately 17.16 billion US dollars in 2020, the figure rises to nearly 37.76 billion US dollars by 2024. This growth indicates an expansion in the company's asset base, reflecting additional investments, acquisitions, or accumulations of operational assets.
- Stockholders’ equity
- Stockholders’ equity also shows significant growth over the analyzed period. It almost doubles from 11.03 billion US dollars in 2020 to about 29.35 billion US dollars in 2024. This increase suggests a strengthening of the company’s financial position, possibly due to retained earnings, issuance of equity, or other factors enhancing shareholders' claim on assets.
- Financial leverage
- Financial leverage, expressed as a ratio, demonstrates a gradual decline from 1.56 in 2020 to 1.27 by 2023, with a slight increase to 1.29 in 2024. This downward trend signifies a reduction in the reliance on debt relative to equity over the years, implying improving solvency and potentially lower financial risk. The minor uptick in 2024 suggests a marginal increase in leverage but remains near the lowest levels in the dataset.
Overall, the company shows strong asset growth complemented by a substantial rise in equity, while financial leverage trends suggest cautious management of debt levels. This combination may indicate an improving financial stability and robustness in capital structure over the observed timeframe.
Interest Coverage
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||
Net income | ||||||
Add: Income tax expense | ||||||
Add: Interest expense | ||||||
Earnings before interest and tax (EBIT) | ||||||
Solvency Ratio | ||||||
Interest coverage1 | ||||||
Benchmarks | ||||||
Interest Coverage, Competitors2 | ||||||
AbbVie Inc. | ||||||
Amgen Inc. | ||||||
Bristol-Myers Squibb Co. | ||||||
Danaher Corp. | ||||||
Eli Lilly & Co. | ||||||
Gilead Sciences Inc. | ||||||
Johnson & Johnson | ||||||
Merck & Co. Inc. | ||||||
Pfizer Inc. | ||||||
Thermo Fisher Scientific Inc. | ||||||
Vertex Pharmaceuticals Inc. | ||||||
Interest Coverage, Sector | ||||||
Pharmaceuticals, Biotechnology & Life Sciences | ||||||
Interest Coverage, Industry | ||||||
Health Care |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 2024 Calculation
Interest coverage = EBIT ÷ Interest expense
= ÷ =
2 Click competitor name to see calculations.
The financial data indicates notable fluctuations in key profitability and solvency metrics over the five-year period.
- Earnings before interest and tax (EBIT)
- EBIT demonstrates significant variability, starting at 3,867,300 thousand US dollars in 2020 and rising sharply to a peak of 9,383,100 thousand US dollars in 2021. This is followed by a pronounced decline in 2022 to 4,918,200 thousand US dollars, a further decrease in 2023 to 4,272,300 thousand US dollars, and a partial recovery in 2024 to 4,835,100 thousand US dollars. The trend suggests a highly volatile operating performance with a major peak in 2021, after which earnings stabilized at a lower level but showed improvement in the final year.
- Interest Expense
- Interest expense remains relatively stable with minor fluctuations, starting at 56,900 thousand US dollars in 2020 and slightly increasing to 57,300 thousand US dollars in 2021 and 59,400 thousand US dollars in 2022. There is a more noticeable increase in 2023 to 73,000 thousand US dollars before decreasing to 55,200 thousand US dollars in 2024. Overall, interest expenses remain low compared to EBIT values, indicating manageable borrowing costs despite the increase in 2023.
- Interest Coverage Ratio
- The interest coverage ratio follows the volatility in EBIT, starting at a high level of 67.97 in 2020 and peaking dramatically at 163.75 in 2021, coinciding with the highest EBIT figure in the period. It then declines substantially to 82.8 in 2022 and further to 58.52 in 2023, reflecting the reduction in operating profit relative to consistent interest expenses. The ratio improves in 2024 to 87.59, corresponding with the partial EBIT recovery. Throughout the period, the interest coverage ratio remains well above typical risk thresholds, indicating strong ability to meet interest obligations despite the EBIT fluctuations.
Fixed Charge Coverage
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||
Net income | ||||||
Add: Income tax expense | ||||||
Add: Interest expense | ||||||
Earnings before interest and tax (EBIT) | ||||||
Add: Operating lease costs | ||||||
Earnings before fixed charges and tax | ||||||
Interest expense | ||||||
Operating lease costs | ||||||
Fixed charges | ||||||
Solvency Ratio | ||||||
Fixed charge coverage1 | ||||||
Benchmarks | ||||||
Fixed Charge Coverage, Competitors2 | ||||||
AbbVie Inc. | ||||||
Amgen Inc. | ||||||
Bristol-Myers Squibb Co. | ||||||
Danaher Corp. | ||||||
Eli Lilly & Co. | ||||||
Gilead Sciences Inc. | ||||||
Johnson & Johnson | ||||||
Merck & Co. Inc. | ||||||
Pfizer Inc. | ||||||
Thermo Fisher Scientific Inc. | ||||||
Vertex Pharmaceuticals Inc. | ||||||
Fixed Charge Coverage, Sector | ||||||
Pharmaceuticals, Biotechnology & Life Sciences | ||||||
Fixed Charge Coverage, Industry | ||||||
Health Care |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 2024 Calculation
Fixed charge coverage = Earnings before fixed charges and tax ÷ Fixed charges
= ÷ =
2 Click competitor name to see calculations.
The financial data over the five-year period exhibits notable fluctuations in earnings before fixed charges and tax, fixed charges, and fixed charge coverage.
- Earnings before Fixed Charges and Tax
-
This metric shows a significant increase in 2021, rising sharply from approximately 3.88 billion US dollars in 2020 to about 9.39 billion US dollars. However, in the subsequent years, it declines to 4.93 billion in 2022 and further decreases to 4.29 billion in 2023. There is a modest recovery in 2024, with earnings increasing to approximately 4.87 billion USD, though it remains below the 2021 peak.
- Fixed Charges
-
Fixed charges have steadily increased over the period, starting at 67.2 million USD in 2020 and gradually moving up to 67.6 million in 2021, then 71.8 million in 2022. A sharper rise is evident in 2023 to 92.2 million USD, remaining nearly stable in 2024 at 91.7 million USD.
- Fixed Charge Coverage Ratio
-
The fixed charge coverage ratio, which indicates the company's ability to cover fixed charges with its earnings before fixed charges and tax, mirrors the volatility of earnings before charges. It peaks dramatically in 2021 at 138.96, reflecting the spike in earnings. This ratio then declines to 68.67 in 2022, further slips to 46.55 in 2023, and recovers slightly to 53.13 in 2024. Despite this recovery, the coverage ratio remains notably lower than the high point achieved in 2021.